About Careers MedBlog Contact us

NICE Rejects Lucentis for Diabetic Macular Edema

by Kathy Jones on March 4, 2011 at 9:09 PM
Font : A-A+

 NICE Rejects Lucentis for Diabetic Macular Edema

Leading drug maker Novartis received a major blow on Friday after the British health agency revealed that it has rejected the approval for Lucentis for treating Diabetic Macular Oedema (DMO).

Lucentis has been in news for some time due to its heavy price tag with the drug costing over $1,200 for each injection. The drug was discovered by Roche's US biotech firm, Genentech, and has proved to be successful for both Novartis and Roche, with annual sales exceeding $1.5 billion.


Though Lucentis is already available in the British market, with the National Institute for Health and Clinical Excellence (NICE) approving it for wet age-related macular degeneration, the health agency felt that the drug did not provide value for money when treating DMO.

Instead Roche's cancer drug, Avastin, has proven to be as effective in treating DMO and is available at a fraction of Lucentis' price at $50 per injection.

Source: Medindia

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

NICE Rejects Lucentis for Diabetic Macular Edema Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests